The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Vol.
51
No.
19
May 16, 2025May 16, 2025
DOWNLOAD THE PDF
The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives In a time of uncertainty, “react to the knowns, not the fear”
Cover Story
PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives

In a time of uncertainty, “react to the knowns, not the fear”
By Katie Goldberg
The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives In a time of uncertainty, “react to the knowns, not the fear”
Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges
Capitol Hill
By Jacquelyn Cobb and Claire Marie Porter
Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
Clinical
By Jacquelyn Cobb
An opportunity for Trump: Position U.S. cancer science to lead the world
Guest Editorial
By Wafik S. El-Deiry
First exhibit at Museum of Medicine and Biomedical Discovery to focus on the history of cancer research From despair to discovery to triumph
FreeGuest Editorial
By Mace L. Rothenberg
City of Hope research showcases innovation at 2025 AACR annual meeting
Sponsored
By City of Hope
Ashtrays in ivory towers: Two centuries of tobacco’s ties to academia
FreeIn the Archives

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account